CassiasideCAS# 123914-49-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 123914-49-8 | SDF | Download SDF |
| PubChem ID | 164146 | Appearance | Powder |
| Formula | C20H20O9 | M.Wt | 404.4 |
| Type of Compound | Phenols | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 5-hydroxy-2-methyl-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzo[g]chromen-4-one | ||
| SMILES | CC1=CC(=O)C2=C(O1)C=C3C=CC=C(C3=C2O)OC4C(C(C(C(O4)CO)O)O)O | ||
| Standard InChIKey | SBVZTBIAKFTNIJ-CZNQJBLBSA-N | ||
| Standard InChI | InChI=1S/C20H20O9/c1-8-5-10(22)15-12(27-8)6-9-3-2-4-11(14(9)17(15)24)28-20-19(26)18(25)16(23)13(7-21)29-20/h2-6,13,16,18-21,23-26H,7H2,1H3/t13-,16-,18+,19-,20-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Cassiaside and emodi show mixed-type inhibition against β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1). 2. Cassiaside demonstrates significant antimutagenic activity. 3. Cassiaside shows 1,1-diphenyl-2-picrylhydrazyl(DPPH) radical scavenging effect. 4. Cassiaside has significant hepato-protective effects against galactosamine damage, which is higher than that of silybin from Silybum marianum. |
| Targets | AChR | BChE |
Cassiaside Dilution Calculator
Cassiaside Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4728 mL | 12.364 mL | 24.728 mL | 49.456 mL | 61.82 mL |
| 5 mM | 0.4946 mL | 2.4728 mL | 4.9456 mL | 9.8912 mL | 12.364 mL |
| 10 mM | 0.2473 mL | 1.2364 mL | 2.4728 mL | 4.9456 mL | 6.182 mL |
| 50 mM | 0.0495 mL | 0.2473 mL | 0.4946 mL | 0.9891 mL | 1.2364 mL |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2473 mL | 0.4946 mL | 0.6182 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Gentiside J
Catalog No.:BCN7306
CAS No.:1238837-50-7
- PCA 4248
Catalog No.:BCC6699
CAS No.:123875-01-4
- UNC0321
Catalog No.:BCC4142
CAS No.:1238673-32-9
- Kazinol U
Catalog No.:BCN4720
CAS No.:1238116-48-7
- Hopeachinol B
Catalog No.:BCN3445
CAS No.:1238083-45-8
- Hydroxyevodiamine
Catalog No.:BCN2491
CAS No.:1238-43-3
- QNZ 46
Catalog No.:BCC6292
CAS No.:1237744-13-6
- ML 786 dihydrochloride
Catalog No.:BCC7997
CAS No.:1237536-18-3
- Escin IA
Catalog No.:BCN3862
CAS No.:123748-68-5
- Aucherine
Catalog No.:BCN2058
CAS No.:123715-12-8
- Acetyl-Calpastatin (184-210) (human)
Catalog No.:BCC2350
CAS No.:123714-50-1
- Moracin O
Catalog No.:BCN4004
CAS No.:123702-97-6
- (R)-(+)-HA-966
Catalog No.:BCC6588
CAS No.:123931-04-4
- Hypocrellin B
Catalog No.:BCN3397
CAS No.:123940-54-5
- Topotecan
Catalog No.:BCC5646
CAS No.:123948-87-8
- Decane
Catalog No.:BCN8138
CAS No.:124-18-5
- Isoborneol
Catalog No.:BCN7158
CAS No.:124-76-5
- Picrotoxin
Catalog No.:BCC5705
CAS No.:124-87-8
- Oxycodone hydrochloride
Catalog No.:BCC6090
CAS No.:124-90-3
- Triamcinolone
Catalog No.:BCC4741
CAS No.:124-94-7
- 1beta,10beta-Epoxydesacetoxymatricarin
Catalog No.:BCN7307
CAS No.:124020-39-9
- Kobophenol A
Catalog No.:BCN3444
CAS No.:124027-58-3
- AZD3514
Catalog No.:BCC1070
CAS No.:1240299-33-5
- 7',8'-Dihydroobolactone
Catalog No.:BCN7196
CAS No.:1240403-82-0
New antihepatotoxic naphtho-pyrone glycosides from the seeds of Cassia tora.[Pubmed:2740460]
Planta Med. 1989 Jun;55(3):276-80.
Two new naphtho-pyrone glycosides, 9-[(beta-D-glucopyranosyl-(1----6)-O-beta-D-glucopyranosyl)oxy]-10- hydroxy-7-methoxy-3-methyl-1H-naphtho[2,3-c]pyran-1 -one (5) and 6-[(alpha-apiofuranosyl-(1----6)-O-beta-D-glucopyranosyl)oxy]- rubrofusarin (6), together with Cassiaside (3) and rubrofusarin-6-beta-gentiobioside (4) were isolated from the seeds of Cassia tora L. Their structures were elucidated on the basis of chemical and spectral data. The naphtho-gamma-pyrone glycosides (3, 4, and 6) were found to have significant hepato-protective effects against galactosamine damage, which were higher than that of silybin from Silybum marianum.
In vitro antimutagenic effects of anthraquinone aglycones and naphthopyrone glycosides from Cassia tora.[Pubmed:9063089]
Planta Med. 1997 Feb;63(1):11-4.
The antimutagenic activity of a methanol extract of Cassia tora seeds against aflatoxin B1(AFB1) was demonstrated with the Salmonella typhimurium assay. The numbers of revertants per plate decreased significantly when this extract was added to the assay system using Salmonella typhimurium TA100 and/or TA98. The MeOH extract was then sequentially partitioned with CH2Cl2, n-BuOH and H2O. The CH2Cl2 and n-BuOH fractions possessed antimutagenic activity but the H2O fraction was inactive. Neither the MeOH extract nor its fractions were capable of inhibiting the direct-acting mutagen N-methyl-N'-nitro-N-nitrosoguanidine suggesting that these fractions may prevent the metabolic activation of AFB1 or scavenge the electrophilic intermediate capable of inducing mutations. Column chromatography using silica gel yielded pure chrysophanol, chryso-obtusin, and aurantio-obtusin from the CH2Cl2 fraction and Cassiaside and rubro-fusarin gentiobioside from the n-BuOH fraction. Each of these compounds demonstrated significant antimutagenic activity.
Alaternin, cassiaside and rubrofusarin gentiobioside, radical scavenging principles from the seeds of Cassia tora on 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical.[Pubmed:10319159]
Arch Pharm Res. 1994 Dec;17(6):462-6.
Radical scavenging principles on 1,1-diphenyl-2-picrylhydrazyl(DPPH) radical were isolated from the seeds of Cassia tora L. Assignments of the 1H- and 13C-NMR data showed the active components to be an anthraquinone, alaternin and two naphthopyrone glycosides, nor-rubrofusarin-6-beta-D-glucoside(Cassiaside) and rubrofusarin-6- -D-gentiobioside. Alaternin showed more potent radical scavenging effect than the others.
Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against beta-secretase and cholinesterases.[Pubmed:27321278]
J Ethnopharmacol. 2016 Sep 15;191:152-160.
ETHNOPHARMACOLOGICAL RELEVANCE: Semen Cassiae has been traditionally used as an herbal remedy for liver, eye, and acute inflammatory diseases. Recent pharmacological reports have indicated that Cassiae semen has neuroprotective effects, attributable to its anti-inflammatory actions, in ischemic stroke and Alzheimer's disease (AD) models. AIM OF THE STUDY: The basic goal of this study was to evaluate the anti-AD activities of C. obtusifolia and its major constituents. Previously, the extract of C. obtusifolia seeds, was reported to have memory enhancing properties and anti-AD activity to ameliorate amyloid beta-induced synaptic dysfunction. However, the responsible components of C. obtusifolia seeds in an AD are currently still unknown. In this study, we investigated the inhibitory effects of C. obtusifolia and its constituents against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and beta-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) enzyme activity. MATERIALS AND METHODS: In vitro cholinesterase enzyme assays by using AChE, BChE, and BACE1 were performed. We also scrutinized the potentials of Cassiae semen active component as BACE1 inhibitors via enzyme kinetics and molecular docking simulation. RESULTS: In vitro enzyme assays demonstrated that C. obtusifolia and its major constituents have promising inhibitory potential against AChE, BChE, and BACE1. All Cassiae semen constituents exhibited potent inhibitory activities against AChE and BACE1 with IC50 values of 6.29-109microg/mL and 0.94-190microg/mL, whereas alaternin, questin, and toralactone gentiobioside exhibited significant inhibitory activities against BChE with IC50 values of 113.10-137.74microg/mL. Kinetic study revealed that alaternin noncompetitively inhibited, whereas Cassiaside and emodin showed mixed-type inhibition against BACE1. Furthermore, molecular docking simulation results demonstrated that hydroxyl group of alaternin and emodin tightly interacted with the active site residues of BACE1 and their relevant binding energies (-6.62 and -6.89kcal/mol), indicating a higher affinity and tighter binding capacity of these compounds for the active site of BACE1. CONCLUSION: The findings of the present study suggest the potential of C. obtusifolia and its major constituents for use in the development of therapeutic or preventive agents for AD, especially through inhibition of AChE, BChE and BACE1 activities.
